Many testicular cancer survivors experience hearing loss after cisplatin-based chemotherapy, according to researchers at Indiana University. The researchers, led by Lois B. Travis, M.D., Sc.D., the ...
Please provide your email address to receive an email when new articles are posted on . A longitudinal cohort study has yielded new insights into risks for and long-term effects of cisplatin-related ...
Hosted on MSN
New machine learning tool predicts a child's personal risk for cisplatin-induced hearing loss
The powerful chemotherapy drug cisplatin has been used since the late 1970s to treat a variety of cancers. It's highly effective against solid tumors and is often a core element of treatment for ...
Detailed price information for Fennec Pharmaceuticals Inc (FENC-Q) from The Globe and Mail including charting and trades.
Please provide your email address to receive an email when new articles are posted on . Cisplatin can permanently damage sensory hair cells in the inner ear and cause hearing loss. A novel drug ...
A widely-used chemotherapy drug used in cancer treatments could greatly increase patients’ long-term risk of hearing loss, according to a study by researchers at Indiana University and the University ...
Many adult survivors of testicular cancer have significant cisplatin-related hearing loss, and about 40% also experience tinnitus, the most comprehensive study to date on this issue has found.
Cisplatin-based chemotherapy can cause immediate and permanent hearing loss, affecting both cancer and sensory cells in the inner ear. A study found that 78 out of 100 testicular cancer survivors ...
LOS ANGELES--(BUSINESS WIRE)--An international research team led by Etan Orgel, MD at Children’s Hospital Los Angeles (CHLA) has developed a novel machine learning model that can predict an individual ...
(RTTNews) - Fennec Pharmaceuticals Inc. (FENC), Friday announced that the National Institute for Health and Care Excellence or NICE has recommended Pedmarqsi, intended for the prevention of ...
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results